OBR Daily Commentary

forumImage

For Bristol-Myers, A Victory And A Mystery

(Forbes) Apr 3, 2017 - New data presented at a medical conference show that combining Bristol-Myers Squibb’s two immune-boosting cancer drugs extends the lives of melanoma patients longer than using either alone.

Read Article arrow

Winston Wong, PharmD (Posted: April 07, 2017)

quotesA commendable increase of 28 months of survival ... and the overall cost is? Not trying to put a price tag on improved survival but we have to consider the cost of the combination regimen, at least from the patient perspective. As for the difference between the BMS and Merck products, payers believe the difference lies in the study design and the PD-L1 testing.quotes

Add Comment 1 Comment
forumImage

Inside the Overlooked Battle Between Drug Makers and Insurers Over Chemotherapy

(STAT Plus) Mar 31, 2017 - In a high-stakes battle between drug makers and insurers, last week it was the drug makers who got a lift, on a little-noticed issue and in an unusual place: Arkansas.

Read Article arrow

Winston Wong, PharmD (Posted: April 02, 2017)

quotesAgreed that the individual patient may see relief. The bigger picture is that if the individual patient does not pay the higher copay, the cost is spread across the entire insured population in the premium. At the end of the day, the costs are high and someone ends up paying for it.quotes

Add Comment 1 Comment
forumImage

Soon-Shiong’s Promotion Of ‘Breakthrough’ Cancer Therapy Raises Questions

(STAT) Mar 27, 2017 - The emotional video tells of a patient with blood cancer who tries an experimental therapy involving “natural killer” cells. “NEW BREAKTHROUGH HELPS PATIENTS KILL CANCER” the banner headline declares as the patient, wiping away tears, covers her face with her hands and murmurs, “It’s really good news.”

Read Article arrow

Winston Wong, PharmD (Posted: April 02, 2017)

quotesOk. So maybe the there was a bit of overexcitement from NantKwest's product. Let's look beyond that and see what the total umbrella of NantHealth is aiming for ... a totally integrated decision support tool, with all of the bells and whistles one could ever imagine or want. In the end, is there an ROI, or will it just be placed alongside of the the other decision support tools, waiting for true clinical utility and an ROI to be proven. IT integration is a powerful tool, and as of yet, we have not achieved it in reality, but at least NantHealth is setting a vision.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...